Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of January 2026
Date Filed: January 21, 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a cover for an exhibit rather than a standalone financial report.
Material Changes
The filing text does not provide data to compare against prior periods. No material changes in financial position are detailed in the provided content.
Guidance, Outlook, and Risks
Exhibit Included: Exhibit 99.1 contains an "ATH Shareholder Letter January 2026."
Management Commentary: The filing itself contains no direct commentary, guidance, or risk factors. Specific details regarding outlook or contingencies are contained within the referenced shareholder letter, which is not included in the input text.
Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Investor Verification Checklist
- Review the full text of Exhibit 99.1 (ATH Shareholder Letter January 2026) for operational updates and financial commentary.
- Verify the status of the referenced Registration Statements on Form S-8 and Form F-3.
- Confirm the company's current cash runway and funding status, as the filing identifies the entity as a "development stage enterprise" without providing current liquidity figures.